volume 21 issue 2 pages 83-88

2021 FDA approvals

Asher Mullard
Publication typeJournal Article
Publication date2022-01-04
scimago Q1
wos Q1
SJR30.506
CiteScore181.8
Impact factor101.8
ISSN14741776, 14741784
Drug Discovery
General Medicine
Pharmacology
Abstract
The FDA approved 50 novel drugs in 2021, including the first KRAS inhibitor for cancer and the first anti-amyloid antibody for Alzheimer’s disease. The FDA approved 50 novel drugs in 2021, including the first KRAS inhibitor for cancer and the first anti-amyloid antibody for Alzheimer’s disease.
Found 

Top-30

Journals

1
2
3
4
Drug Discovery Today
4 publications, 3.81%
International Journal of Molecular Sciences
3 publications, 2.86%
European Journal of Medicinal Chemistry
3 publications, 2.86%
Journal of Medicinal Chemistry
3 publications, 2.86%
Cancers
2 publications, 1.9%
Molecular Pharmaceutics
2 publications, 1.9%
Nature Communications
2 publications, 1.9%
Scientific Reports
2 publications, 1.9%
Journal of the American Society of Nephrology : JASN
1 publication, 0.95%
Biomedicines
1 publication, 0.95%
Biomolecules
1 publication, 0.95%
Molecules
1 publication, 0.95%
Antibodies
1 publication, 0.95%
International Journal of Impotence Research
1 publication, 0.95%
Nature Reviews Chemistry
1 publication, 0.95%
Journal of Solution Chemistry
1 publication, 0.95%
Journal of General Internal Medicine
1 publication, 0.95%
InFo Hämatologie + Onkologie
1 publication, 0.95%
European Review of Aging and Physical Activity
1 publication, 0.95%
The Lancet Oncology
1 publication, 0.95%
Regulatory Toxicology and Pharmacology
1 publication, 0.95%
Analytical Science Advances
1 publication, 0.95%
Bioengineering & Translational Medicine
1 publication, 0.95%
Advanced Materials
1 publication, 0.95%
Analytical Chemistry
1 publication, 0.95%
Entrepreneurship and Innovation Policy and the Economy
1 publication, 0.95%
Medicinal Research Reviews
1 publication, 0.95%
Frontiers in Pharmacology
1 publication, 0.95%
Journal of Chemical Theory and Computation
1 publication, 0.95%
1
2
3
4

Publishers

5
10
15
20
25
Springer Nature
22 publications, 20.95%
Elsevier
17 publications, 16.19%
Wiley
14 publications, 13.33%
American Chemical Society (ACS)
13 publications, 12.38%
MDPI
11 publications, 10.48%
Oxford University Press
5 publications, 4.76%
Taylor & Francis
3 publications, 2.86%
Frontiers Media S.A.
2 publications, 1.9%
Cold Spring Harbor Laboratory
2 publications, 1.9%
Royal Society of Chemistry (RSC)
2 publications, 1.9%
Bentham Science Publishers Ltd.
2 publications, 1.9%
American Society of Nephrology
1 publication, 0.95%
University of Chicago Press
1 publication, 0.95%
American Association for the Advancement of Science (AAAS)
1 publication, 0.95%
Canadian Science Publishing
1 publication, 0.95%
Society of Hospital Medicine
1 publication, 0.95%
IntechOpen
1 publication, 0.95%
Medknow
1 publication, 0.95%
Institute of Electrical and Electronics Engineers (IEEE)
1 publication, 0.95%
Ovid Technologies (Wolters Kluwer Health)
1 publication, 0.95%
Georg Thieme Verlag KG
1 publication, 0.95%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 0.95%
5
10
15
20
25
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
105
Share
Cite this
GOST |
Cite this
GOST Copy
Mullard A. 2021 FDA approvals // Nature Reviews Drug Discovery. 2022. Vol. 21. No. 2. pp. 83-88.
GOST all authors (up to 50) Copy
Mullard A. 2021 FDA approvals // Nature Reviews Drug Discovery. 2022. Vol. 21. No. 2. pp. 83-88.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1038/d41573-022-00001-9
UR - https://doi.org/10.1038/d41573-022-00001-9
TI - 2021 FDA approvals
T2 - Nature Reviews Drug Discovery
AU - Mullard, Asher
PY - 2022
DA - 2022/01/04
PB - Springer Nature
SP - 83-88
IS - 2
VL - 21
PMID - 34983958
SN - 1474-1776
SN - 1474-1784
ER -
BibTex |
Cite this
BibTex (up to 50 authors) Copy
@article{2022_Mullard,
author = {Asher Mullard},
title = {2021 FDA approvals},
journal = {Nature Reviews Drug Discovery},
year = {2022},
volume = {21},
publisher = {Springer Nature},
month = {jan},
url = {https://doi.org/10.1038/d41573-022-00001-9},
number = {2},
pages = {83--88},
doi = {10.1038/d41573-022-00001-9}
}
MLA
Cite this
MLA Copy
Mullard, Asher. “2021 FDA approvals.” Nature Reviews Drug Discovery, vol. 21, no. 2, Jan. 2022, pp. 83-88. https://doi.org/10.1038/d41573-022-00001-9.